Latest Articles
Christie's pain was dismissed for decades, then she developed 'terminal' endometriosis - 9News
Christie's pain was dismissed for decades, then she developed 'terminal' endometriosis 9News
Published: July 2, 2024, 7 a.m.
Scientists discover high-risk form of endometrial cancer—and how to test for it—using AI - Medical Xpress
Scientists discover high-risk form of endometrial cancer—and how to test for it—using AI Medical Xpress
Published: June 26, 2024, 7 a.m.
AstraZeneca mAb Approved by FDA for Endometrial Cancer Patients - BioPharm International
AstraZeneca mAb Approved by FDA for Endometrial Cancer Patients BioPharm International
Published: June 20, 2024, 7 a.m.
FDA approves MSD’s KEYTRUDA for endometrial carcinoma - Pharmaceutical Technology
FDA approves MSD’s KEYTRUDA for endometrial carcinoma Pharmaceutical Technology
Published: June 18, 2024, 7 a.m.
Novel immunotherapy combination approved for endometrial cancer - European Pharmaceutical Review
Novel immunotherapy combination approved for endometrial cancer European Pharmaceutical Review
Published: June 18, 2024, 7 a.m.
Merck's Keytruda snags 40th US indication, leaps ahead of GSK with broad endometrial cancer approval - FiercePharma
Merck's Keytruda snags 40th US indication, leaps ahead of GSK with broad endometrial cancer approval FiercePharma
Published: June 18, 2024, 7 a.m.
AstraZeneca lands narrow Imfinzi nod in endometrial cancer. Where’s Lynparza? - FiercePharma
AstraZeneca lands narrow Imfinzi nod in endometrial cancer. Where’s Lynparza? FiercePharma
Published: June 17, 2024, 7 a.m.
AstraZeneca Imfinzi regimen for endometrial cancer gains FDA approval - Pharmaceutical Technology
AstraZeneca Imfinzi regimen for endometrial cancer gains FDA approval Pharmaceutical Technology
Published: June 17, 2024, 7 a.m.
FDA Approves AstraZeneca’s Imfinzi for Mismatch Repair Deficient Primary Advanced or Recurrent Endometrial Cancer - Pharmaceutical Executive
FDA Approves AstraZeneca’s Imfinzi for Mismatch Repair Deficient Primary Advanced or Recurrent Endometrial Cancer Pharmaceutical Executive
Published: June 17, 2024, 7 a.m.
Interleukin-1β induces and accelerates human endometrial stromal cell senescence and impairs decidualization via the c-Jun N-terminal kinase pathway | Cell Death Discovery - Nature.com
Interleukin-1β induces and accelerates human endometrial stromal cell senescence and impairs decidualization via the c-Jun N-terminal kinase pathway | Cell Death Discovery Nature.com
Published: June 15, 2024, 7 a.m.
Link copied to clipboard!